Quirem Medical B.V.
http://www.quirem.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Quirem Medical B.V.
Padagis Hit With Immediate Suit After Filing First ANDA For US Zoryve Cream
Tipped to bring in sales of $500m or more by 2030, Arcutis Biotherapeutics’ Zoryve 0.3% cream has become the target of an ANDA filed by Padagis, a partner of Sol-Gel Technologies. The originator responded with an immediate suit to shut down any potential generic launch in the near term.
Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
Hyloris Announces Approval Of Condylox First Generic
Hyloris has received US approval for its generic podofilox gel, previously referred to as HY-016.
Padagis Seeks To Challenge Hikma’s Kloxxado
Padagis has set out two first-to-file ANDA submissions in the US, challenging Hikma’s Kloxxado as well as Evofem’s Phexxi. The former Perrigo Rx business has also just launched two limited-competition generics.
Company Information
- Industry
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice